Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer



Status:Completed
Conditions:Ovarian Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:10/25/2017
Start Date:March 2011
End Date:November 3, 2016

Use our guide to learn which trials are right for you!

A Randomized Phase II Evaluation of Single-Agent Bevacizumab (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

This randomized phase II trial studies how well bevacizumab with or without fosbretabulin
tromethamine works in treating patients with ovarian epithelial, fallopian tube, or
peritoneal cavity cancer that has come back or is persistent. Monoclonal antibodies, such as
bevacizumab, find tumor cells and help kill them. Bevacizumab and fosbretabulin tromethamine
may stop the growth of ovarian cancer by blocking blood flow to the tumor. It is not yet
known whether bevacizumab is more effective with or without fosbretabulin tromethamine in
treating ovarian epithelial, fallopian tube, and peritoneal cavity cancer.

PRIMARY OBJECTIVES:

I. To estimate the progression-free survival hazard ratio of the combination of bevacizumab
and fosbretabulin tromethamine (CA4P) compared to bevacizumab alone in patients with
persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer.

SECONDARY OBJECTIVES:

I. To determine the nature and degree of toxicity of fosbretabulin tromethamine plus
bevacizumab.

II. To characterize and compare progression-free survival in patients with measurable disease
(Response Evaluation Criteria in Solid Tumors [RECIST] criteria) and patients with detectable
(non-measurable) disease between regimens.

III. To determine the overall survival for both regimens. IV. To estimate the proportion of
patients with measurable disease who have objective tumor responses by treatment.

V. To provide descriptive information about cancer antigen (CA)-125 responses by regimen and
where possible by objective tumor responses.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive bevacizumab IV over 30-90 minutes and fosbretabulin tromethamine IV
over 10-20 minutes on day 1. Courses repeat every 21 days in the absence of disease
progression or unacceptable toxicity.

ARM II: Patients receive bevacizumab as in Arm I. Courses repeat every 21 days in the absence
of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years and
then every 6 months for 3 years.

Inclusion Criteria:

- Patients must have recurrent or persistent epithelial ovarian, fallopian tube, or
primary peritoneal carcinoma; histologic documentation of the original primary tumor
is required via the pathology report

- Patients must have measurable disease or detectable (non-measurable) disease:

- Measurable disease defined as at least one lesion that can be accurately measured
in at least one dimension (longest dimension to be recorded); each lesion must be
>= 10 mm when measured by computed tomography (CT) scan, magnetic resonance
imaging (MRI) or caliper measurement by clinical exam, or >= 20 mm when measured
by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or
MRI

- Detectable disease in a patient is defined as one who does not have measurable
disease but has at least one of the following conditions:

- Baseline values of CA-125 at least 2 x upper limit of normal (ULN)

- Ascites and/or pleural effusion attributed to tumor

- Solid and/or cystic abnormalities on radiographic imaging that do not meet
RECIST 1.1 definition for target lesions

- Patients in the measurable disease cohort must have at least one "target lesion" to be
used to assess response on this protocol as defined by RECIST 1.1; tumors within a
previously irradiated field will be designated as "non-target" lesions unless
progression is documented or a biopsy is obtained to confirm persistence at least 90
days following completion of radiation therapy

- Patients must not be eligible for a higher priority Gynecologic Oncology Group (GOG)
protocol, if one exists; in general, this would refer to any active GOG phase 3
protocol or rare tumor protocol for the same patient population

- Patients who have had one prior treatment must have a performance status of 0, 1, or 2

- Patients who have had two or three prior treatments must have a performance status of
0 or 1

- Patients should be free of acute hepatitis and active infection requiring parenteral
antibiotics (with the exception of uncomplicated urinary tract infection [UTI])

- Recovery from the effects of recent surgery, radiotherapy, or chemotherapy

- Any hormonal therapy directed at the malignant tumor must be discontinued at
least one week prior to registration

- Any other prior therapy directed at the malignant tumor, including chemotherapy,
biological/targeted and immunologic agents, must be discontinued at least 3 weeks
prior to registration (including small molecules and murine monoclonal
antibodies); chimeric or human or humanized monoclonal antibodies (including
bevacizumab) or vascular endothelial growth factor (VEGF) receptor fusion protein
(including VEGF Trap/aflibercept) must be discontinued for at least 12 weeks
prior to registration; no investigational therapy within 30 days prior to the
first date of study treatment

- Any prior radiation therapy must be discontinued at least 4 weeks prior to
registration

- Prior therapy:

- Patients must have had one prior platinum-based chemotherapeutic regimen for
management of primary disease containing carboplatin, cisplatin, or another
organoplatinum compound; this initial treatment may have included intraperitoneal
therapy, consolidation, non-cytotoxic (biologic/targeted agents, such as
bevacizumab) or extended therapy administered after surgical or non-surgical
assessment

- Patients are allowed to receive, but are not required to receive, two additional
cytotoxic regimens for management of recurrent or persistent disease, with no
more than 1 non-platinum, non-taxane regimen

- Patients are allowed to receive, but are not required to receive, non-cytotoxic
(biologic/targeted agents, such as bevacizumab) therapy as part of their primary
treatment regimen; patients must have NOT received any non-cytotoxic therapy
(biologic/targeted agents) for management of recurrent or persistent disease
(e.g., GOG protocol 170 series drugs or bevacizumab)

- For the purposes of this study, poly (adenosine diphosphate [ADP]-ribose)
polymerase (PARP) inhibitors will be considered "cytotoxic", and prior treatment
with PARP inhibitors for primary or recurrent disease WILL be allowed (either
alone or in combination with chemotherapy)

- Patients with both platinum-sensitive and platinum-resistant disease are eligible;
patients with platinum-refractory disease are NOT eligible; platinum-refractory
disease is defined as patients who have progression of disease during the preceding
platinum treatment

- Definitions:

- Platinum-free interval (PFI) is the period of time from the date of last
platinum therapy to the date of progression (recurrence by CA-125, CT, etc.;
CT is preferred) of disease or initiation of subsequent therapy (whichever
occurs first); non-platinum maintenance therapy (e.g., extending taxane
treatment) is excluded as a "subsequent therapy;" if the patient's last
regimen used platinum, and she has NOT progressed before enrolling onto this
study, then her PFI will be calculated from the date of last platinum
therapy to the date of registration onto this study

- PFI for the most recent platinum therapy will need to be calculated before
enrollment onto this study for stratification purposes (i.e. balanced
randomization)

- Patients who have a PFI =< 182 days (26 weeks) are defined as "platinum
resistant;" patients who have 182 < PFI =< 365 days are defined as "GOG
platinum sensitive;" finally, patients with PFI > 365 days are defined as
"platinum sensitive"

- ANC greater than or equal to 1,500/mcl

- Platelets greater than or equal to 100,000/mcl

- Hemoglobin greater than or equal to 9 g/dL

- Creatinine less than or equal to 1.5 x institutional upper limit of normal (ULN)

- Potassium within the normal reference range for the laboratory; correction with
supplements is acceptable

- Magnesium within the normal reference range for the laboratory; correction with
supplements is acceptable

- Calcium within the normal reference range for the laboratory; correction with
supplements is acceptable

- Bilirubin less than or equal to 1.5 x ULN

- Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =<
less than or equal to 3 x ULN

- Alkaline phosphatase less than or equal to 2.5 x ULN

- Prothrombin time (PT) such that international normalized ratio (INR) is less than or
equal to 1.5 x ULN (or an in-range INR, usually between 2 and 3, if a patient is on a
stable dose of therapeutic warfarin) and a partial thromboplastin time (PTT) less than
or equal to 1.5 x ULN

- Urine protein should be screened by urine analysis; if protein is 2+ or higher, a
24-hour urine protein should be obtained and the level must be < 1,000 mg (< 1.0 g/24
hrs) for patient enrollment

- Patients of childbearing potential must have a negative serum pregnancy test prior to
the study entry and be practicing an effective form of contraception

- Patients must have signed an approved informed consent and authorization permitting
the release of personal health information

- Patients must meet pre-entry requirements

Exclusion Criteria:

- Patients who have received prior fosbretabulin tromethamine or any other vascular
disrupting agent (VDA)

- Patients with other invasive malignancies, with the exception of non-melanoma skin
cancer and other specific malignancies as noted below, are excluded if there is any
evidence of other malignancy being present within the last three years; patients are
also excluded if their previous cancer treatment contraindicates this protocol therapy

- Patients who have received prior radiotherapy to any portion of the abdominal cavity
or pelvis OTHER THAN for the treatment of ovarian, fallopian tube or primary
peritoneal cancer within the last three years are excluded; prior radiation for
localized cancer of the breast, head and neck, or skin is permitted, provided that it
was completed more than three years prior to registration, and the patient remains
free of recurrent or metastatic disease

- Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER
THAN for the treatment of ovarian, fallopian tube or primary peritoneal cancer within
the last three years are excluded; patients may have received prior adjuvant
chemotherapy for localized breast cancer, provided that it was completed more than
three years prior to registration, and the patient remains free of recurrent or
metastatic disease

- Patients with serious non-healing wound, ulcer, or bone fracture; this includes
history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess
within 90 days prior to the first date of study treatment

- Patients with active bleeding or pathologic conditions that carry high risk of
bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major
vessels

- Patients with history or evidence upon physical examination of central nervous system
(CNS) disease, including primary brain tumor, seizures not controlled with standard
medical therapy, any brain metastases, or history of cerebrovascular accident (CVA,
stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months
prior to the first date of treatment on this study

- Patients with clinically significant cardiovascular disease; this includes:

- Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm
Hg despite antihypertensive medications

- History of torsade de pointes, ventricular tachycardia or fibrillation,
pathologic sinus bradycardia (< 60 beats per minute [bpm]), heart block
(excluding 1st degree block being, PR interval prolongation only), congenital
long QT syndrome, new ST segment elevation or depression, or new Q waves on
electrocardiogram (ECG)

- Patients with corrected QT interval (QTc) > 470 msec

- Requirement for receiving any drug known to prolong the QTc interval, including
anti-arrhythmic medications; stable regimen of antidepressants of the selective
serotonin reuptake inhibitor (SSRI) class is allowed

- Myocardial infarction or unstable angina within 6 months prior to registration

- New York Heart Association (NYHA) class II or greater congestive heart failure

- Serious cardiac arrhythmia requiring medication; this does not include
asymptomatic, atrial fibrillation with controlled ventricular rate

- Patients who have received prior treatment with an anthracycline (including
doxorubicin and or pegylated liposomal doxorubicin [Doxil; PLD]) must have an
echocardiogram assessment and are excluded if they have an ejection fraction <
50%

- Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or greater
peripheral vascular disease (at least brief [< 24 hrs] episodes of ischemia
managed non-surgically and without permanent deficit)

- Known hypersensitivity to any of the components of fosbretabulin tromethamine or
bevacizumab

- Major surgery within 28 days prior to the first date of study treatment

- Anticipation of need for major surgical procedures during the course of the study

- Core biopsy within 7 days prior to the first date of study treatment

- Patients with clinical symptoms or signs of gastrointestinal obstruction and patients
who require parenteral hydration and/or nutrition; patients with bowel involvement on
CT scan

- Patients with medical history or conditions not otherwise previously specified which
in the opinion of the investigator should exclude participation in this study; the
investigator can consult the Study Chair or Study Co-Chairs for uncertainty in this
regard

- Patients who are pregnant or nursing
We found this trial at
51
sites
Portland, Maine 04102
?
mi
from
Portland, ME
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
(269) 341-7654
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
(804) 828-0450
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
?
mi
from
Akron, OH
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
2401 W Belvedere Ave
Baltimore, Maryland 21215
(410) 601-9000
Sinai Hospital of Baltimore Sinai Hospital of Baltimore provides a broad array of high-quality, cost-effective...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Boise, ID
Click here to add this to my saved trials
?
mi
from
Burbank, CA
Click here to add this to my saved trials
Charlotte, North Carolina 28204
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
1-773-702-6180
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2600 Clifton Ave
Cincinnati, Ohio 45267
(513) 556-6000
University of Cincinnati The University of Cincinnati offers students a balance of educational excellence and...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
18101 Lorain Avenue
Cleveland, Ohio 44111
216.476.7000
Cleveland Clinic Cancer Center at Fairview Hospital Fairview Hospital is a 488-bed hospital located at...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
6001 E Woodmen Rd
Colorado Springs, Colorado 80923
(719) 776-5000
Penrose-Saint Francis Healthcare Founded by the Sisters of St. Francis and the Sisters of Charity,...
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Concord, California 94520
?
mi
from
Concord, CA
Click here to add this to my saved trials
?
mi
from
Denver, CO
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
743 Spring St NE
Gainesville, Georgia 30501
770-219-9000
Northeast Georgia Medical Center Northeast Georgia Health System (NGHS) is a not-for-profit community health system...
?
mi
from
Gainesville, GA
Click here to add this to my saved trials
835 S Van Buren St
Green Bay, Wisconsin 54301
(920) 433-0111
?
mi
from
Green Bay, WI
Click here to add this to my saved trials
1726 Shawano Ave.
Green Bay, Wisconsin 54303
(920) 884-3135
Green Bay Oncology Limited at Saint Mary's Hospital We are one of a select few...
?
mi
from
Green Bay, WI
Click here to add this to my saved trials
835 S. Van Buren St.
Green Bay, Wisconsin 54301
(920) 884-3135
Green Bay Oncology at Saint Vincent Hospital We are one of a select few physician...
?
mi
from
Green Bay, WI
Click here to add this to my saved trials
Greenville, South Carolina 29615
?
mi
from
Greenville, SC
Click here to add this to my saved trials
80 Seymour St
Hartford, Connecticut 6102
(860) 545-5000
The Hartford Hospital Hartford Hospital is the major teaching hospital affiliated with the University of...
?
mi
from
Hartford, CT
Click here to add this to my saved trials
?
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Indianapolis, Indiana 46260
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
535 Barnhill Dr
Indianapolis, Indiana 46202
(888) 600-4822
Indiana University Melvin and Bren Simon Cancer Center At the IU Simon Cancer Center, more...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Jackson, Mississippi 39216
?
mi
from
Jackson, MS
Click here to add this to my saved trials
1521 Gull Rd
Kalamazoo, Michigan 49048
269) 226-7000
Borgess Medical Center At Borgess, healing is our calling. This is the place where people...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
3855 Health Sciences Dr,
La Jolla, California 92093
(858) 822-6100
UC San Diego Moores Cancer Center Established in 1978, UC San Diego Moores Cancer Center...
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
3131 La Canada St # 241
Las Vegas, Nevada 89169
(702) 693-6870
Women's Cancer Center of Nevada The Women's Cancer Center is a recognized leader in the...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
424 Savannah Rd
Lewes, Delaware 19958
(302) 645-3300
Beebe Medical Center Located in beautiful historic Lewes, Delaware, near Rehoboth Beach, Beebe Healthcare offers...
?
mi
from
Lewes, DE
Click here to add this to my saved trials
2300 Western Ave
Manitowoc, Wisconsin 54221
(920) 320-2011
Holy Family Memorial Hospital We are the recognized leader and the largest provider of health...
?
mi
from
Manitowoc, WI
Click here to add this to my saved trials
3100 Shore Drive
Marinette, Wisconsin 54143
715.735.4200
Bay Area Medical Center Bay Area Medical Center was created in 1985, but its history...
?
mi
from
Marinette, WI
Click here to add this to my saved trials
Mayfield Heights, Ohio 44124
?
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Miami, Florida 33133
?
mi
from
Miami, FL
Click here to add this to my saved trials
4755 Ogletown-Stanton Road
Newark, Delaware 19718
302-733-1000
Christiana Care Health System - Christiana Hospital A 913-bed, 1.3-million-square-foot, modern facility in Newark, Delaware,...
?
mi
from
Newark, DE
Click here to add this to my saved trials
940 NE 13th St
Oklahoma City, Oklahoma 73190
(405) 271-6458
University of Oklahoma Health Sciences Center The OU Health Sciences Center is composed of seven...
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19111
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Providence, Rhode Island 02905
?
mi
from
Providence, RI
Click here to add this to my saved trials
Sacramento, California 95816
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Savannah, Georgia 31404
?
mi
from
Savannah, GA
Click here to add this to my saved trials
1305 W 18th St
Sioux Falls, South Dakota 57117
(605) 333-1000
Sanford USD Medical Center - Sioux Falls Sanford
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
1309 W 17th Street
Sioux Falls, South Dakota 57104
(605) 328-8000
Sanford Cancer Center-Oncology Clinic Sanford Health is an integrated health system headquartered in the Dakotas...
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Wheat Ridge, Colorado 80033
?
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials
Worcester, Massachusetts 01605
?
mi
from
Worcester, MA
Click here to add this to my saved trials